pacira.com - PCRX Company Value to Revenue

Public company logo of Pacira Pharmaceuticals (PCRX)

How does the moderate cyclicality of elective surgeries impact the valuation of Pacira BioSciences (PCRX)? The EV/Sales trend displayed on GURU.Markets illustrates the current trajectory, where 2027.92 captures the magnitude of this metric. High-capacity analgesic production facilities ensure stability, while the integration of the EXPAREL platform into hospital protocols as an opioid alternative drives margin growth.

PCRX Pacira Corp: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Pacira (PCRX)

- current quotes and average value forecast:
- issuer market value details:
Fundamental company valuation:Pacira BioSciences - PCRX
Mass-produced product of Pacira Pharmaceuticals

The operational resilience of Pacira BioSciences (PCRX) is based on the stable operation of production facilities for analgesic manufacturing. The EV/Sales ratio, equal to 2027.92, determines the total business value relative to revenue, excluding the impact of debt load. This metric allows for an assessment of sales capitalization efficiency without distortions from leverage. High capacity utilization confirms the fundamental value of the assets. By analyzing the enterprise value to sales chart, an investor can distinguish market volatility from a systemic decline in efficiency.

Competitor analysis for Pacira BioSciences

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio